Nick Leschly, bluebird bio CEO (Jeff Rumans)
After good news in sickle cell, bluebird bio follows up with positive long-term data in Lorenzo’s Oil disease
Less than a week after bluebird bio said their sickle cell gene therapy was “very unlikely” to have caused a case of acute myeloid leukemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
